(Q74579037)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

title

Autoimmune events during interferon beta-1b treatment for multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

L Durelli

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

B Ferrero

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

A Oggero

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

E Verdun

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

M R Bongioanni

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

E Gentile

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

G L Isoardo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

A Ricci

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

E Rota

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

B Bergamasco

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

M Durazzo

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

G Saracco

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

M A Biava

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

P C Brossa

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

L Giorda

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

R Pagni

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

G Aimo

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 January 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

Journal of the Neurological Sciences

11 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

162

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

74-83

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection

11 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Frequency of anti-nuclear antibodies in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Autoimmunity in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Antinuclear antibodies in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Worldwide differences in the incidence of type I diabetes are associated with amino acid variation at position 57 of the HLA-DQ beta chain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Long term recombinant interferon alpha treatment in MS with special emphasis to side effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Interferon treatment for multiple sclerosis: autoimmune complications may be lethal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

MS: a CNS and systemic autoimmune disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Autoimmune hepatitis and chronic hepatitis C: latent or initiated by interferon therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Intravenous natural beta interferon treatment of chronic exacerbating-remitting multiple sclerosis: clinical response and MRI/CSF findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Circulating thyroid and gastric parietal cell autoantibodies in patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Thyroid function in patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Fatal hepatic decompensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Meeting report: International Autoimmune Hepatitis Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Effects of recombinant alpha-2b-interferon therapy in patients with progressive MS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Effects of gamma-interferon on DR antigen expression, growth, 3,5,3'-triiodothyronine secretion, iodide uptake, and cyclic adenosine 3',5'-monophosphate accumulation in cultured human thyroid cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

The role of interferon-gamma in lymphocytic thyroiditis: its functional and pathological effect on human thyrocytes in culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

HLA-DQB1 genotype in Sardinian multiple sclerosis: evidence for a key role of DQB1 *0201 and *0302 alleles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Autoantibodies to the islet antigen ICA 69 occur in IDDM and in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Multiple sclerosis and chronic inflammatory diseases. A case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Side effect profile of interferon beta-1b in MS: results of an open label trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Side effects of high-dose interferon therapy for chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Interferons in multiple sclerosis. A review of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Thyroiditis after treatment with interleukin-2 and interferon alpha-2a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Monocytes in active multiple sclerosis: intact regulation of HLA-DR density in vitro despite decreased HLA-DR density in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Immunological complications in multiple sclerosis patients receiving interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Does interferon beta cause initial exacerbation of multiple sclerosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Autoantibodies and response to alpha-interferon in patients with chronic viral hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Autoimmune hepatitis versus viral hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Clinical toxicity of the interferons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Immune-mediated side-effects of cytokines in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

The epidemiology of thyroid disease and implications for screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

Pathogenesis of inflammatory demyelination: implications for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900299-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-510X(98)00299-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10064173%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference